VMediar Therapeutics doses first patient in phase 2 WISPer trial of MTX-463 for idiopathic pulmonary fibrosis
Mediar Therapeutics, Inc, a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, announced the first patient has been dosed in its phase 2 WISPer clinical trial evaluating MTX-463, an investigational therapy for idiopathic pulmonary fibrosis (IPF).
• The study's primary endpoint is the change from baseline in forced vital capacity (FVC) - an important measure of lung function - at 24 weeks. The study aims to advance the development of a potential novel treatment for patients living with idiopathic pulmonary fibrosis, and targets the myofibroblast, the key pathogenic cell in fibrosis. Mediar recently entered into a global licensing agreement with Lilly to advance MTX-463 through the phase 2 WISPer trial.
• Idiopathic pulmonary fibrosis is a rare and progressive lung disease characterized by scarring and thickening of lung tissue, which leads to increasing shortness of breath and a persistent dry cough.
• Despite available treatments, there remains a high unmet medical need, with an average life expectancy of three to five years’ post-diagnosis.
• The WISPer clinical trial is a randomized, double-blind, placebo-controlled 24 weeks’ phase 2 study designed to evaluate the efficacy, safety, and tolerability of MTX-463 in patients living with idiopathic pulmonary fibrosis.
• "Dosing the first patient in the WISPer trial represents an important step forward in the pursuit of new options to address the urgent needs of individuals living with IPF,"" said Toby Maher, MD, PhD, Director of Interstitial Lung Disease, University of Southern California, and lead investigator in the Phase 2 clinical study.
• "Idiopathic pulmonary fibrosis is a devastating disease with limited treatment options. We are eager to evaluate the potential of MTX-463 to slow or halt disease progression and look forward to the insights this study will provide for patients and their physicians.""
• "Today marks an important milestone in our ongoing commitment to pioneering novel therapies to impact people living with fibrotic diseases. We extend our gratitude to Dr. Ryan Klein and the dedicated team at NewportNativeMD whose expertise and collaboration have been instrumental in reaching this important step,"" said Jeff Bornstein, Chief Medical Officer, Mediar.
• "The first patient dosed with this first-in-class anti-fibrotic marks the beginning of a new chapter in our research, and we look forward to working with our clinical sites as we continue to enroll the phase 2 programme.""
• Mediar is also independently advancing its two wholly owned programs to treat other fibrotic disorders.
• MTX-474, a first-in-class human IgG1 antibody designed to neutralize EphrinB2 signaling, recently completed its phase 1 clinical study.
• Mediar anticipates initiating a phase 2 trial for MTX-474 in systemic sclerosis in the second half of 2025.
• Mediar's third novel fibrosis program, targeting SMOC2 for renal fibrosis, is also advancing with a plan to nominate a clinical candidate in the first half of 2025.
• MTX-463 is a first-in-class human IgG1 antibody developed against WNT1-inducible signaling pathway protein-1 (WISP1).
• WISP1 is a secreted matricellular protein shown to have a relevant role in fibrosis progression, is measurable in human blood, and correlates with disease severity.
• Data indicates that MTX-463 neutralizes WISP1-mediated fibrotic signaling and significantly reduced fibrosis in vitro and in various preclinical models.
• A phase 1 study was recently completed and a phase 2 study in patients with idiopathic pulmonary fibrosis is now open.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!